About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

3-D Cultures Grown from Patients' Tumors may Help Personalize Drug Screening

by Vishnuprasad on May 12, 2015 at 11:29 PM
Font : A-A+

3-D Cultures Grown from Patients' Tumors may Help Personalize Drug Screening

Three-dimensional cultures derived from the tumors of cancer patients closely replicate properties of the original tumors, reveals a new study.

According to the scientists at Wellcome Trust Sanger Institute, UK, these 'organoids' are amenable to large-scale drug screens for the detection of genetic changes associated with drug sensitivity.

Advertisement

The drug screening can pave the way for personalized treatment approaches that could optimize clinical outcomes in cancer patients. "This is the first time that a collection of cancer organoids, or a living biobank, has been derived from patient tumors. We believe that these organoids are an important new tool in the arsenal of cancer biologists and may ultimately improve our ability to develop more effective cancer treatments," says Mathew Garnett, a geneticist at the Institute.

In the new study, the scientists grew 22 organoids from 20 patients with colorectal cancer and then sequenced genomic DNA isolated from these cultures.
Advertisement

The genetic mutations in the cultures closely matched those in the corresponding tumor biopsies and agreed well with previous large-scale analyses of colorectal cancer mutations. These findings confirm that the cultures faithfully capture the genomic features of the tumors from which they are derived as well as much of the genomic diversity associated with colorectal cancer.

The scientist screened the responses of the organoids to 83 cancer drugs. Given their diverse genetic profiles, the organoids displayed a range of sensitivities to the drugs.

The researchers identified previously reported associations between specific mutations and resistance to particular drugs. The organoids also showed a novel gene-drug association, indicating that the subset of cancer patients with RNF43 mutations would strongly benefit from a drug that inhibits a protein called porcupine.

"At some point in the future, this approach may be suitable for modeling individual patient response to cancer therapies to inform clinical treatment," Garnett says. The study was published in the Cell.

Source: Medindia
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Cancer News

 Analyzing Paediatric Brain Tumours Provide Data for Cancer Research
The first large-scale, collaborative, open analysis of genomic data provides a cloud-based resource for researchers looking for more comprehensive data on pediatric brain tumors.
Cancer Drugs to be Tested in Orbit During American Private Astronaut Mission
The mission of Axiom Space incorporated numerous experiments focusing on human stem cell aging, inflammation, and cancer within the laboratory situated in the low Earth orbit.
 Hydrogen Sulfide Makes Cancer Cells More Sensitive to Photothermal Therapy
Providing a sustained supply of hydrogen sulfide to cancer cells, could be a remodeling strategy to improve photothermal therapy efficacy while minimizing side effects.
Hidden Influence of Gut Microbiome on Early-Onset Colorectal Cancer
Colon cancer's hidden link revealed in microbiome study.
Telephone-based Weight Loss Program Helps Breast Cancer Patients Shed Pounds
Breast cancer patients in the obese or overweight category can greatly benefit from a telephone-based weight management program in achieving significant weight loss.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

3-D Cultures Grown from Patients' Tumors may Help Personalize Drug Screening Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests